Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:ANIKOTCMKTS:BNXTFNASDAQ:ELDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.69-0.3%$1.70$1.43▼$4.98$169.69M1.62168,846 shs68,999 shsANIKAnika Therapeutics$11.24-4.5%$13.98$11.11▼$29.12$161.19M0.7670,609 shs59,389 shsBNXTFBioNxt Solutions$0.38+3.7%$0.34$0.11▼$0.43$43.99M0.69,071 shs10,200 shsELDNEledon Pharmaceuticals$3.05+1.0%$3.12$2.30▼$5.54$182.64M0.08272,701 shs175,430 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune+2.73%+7.96%+13.00%-35.80%-50.87%ANIKAnika Therapeutics+0.51%-3.84%-17.05%-32.41%-53.68%BNXTFBioNxt Solutions+3.71%+1.31%+25.95%+1.85%+85.19%ELDNEledon Pharmaceuticals-4.13%+4.50%-10.65%-29.60%+1.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.5988 of 5 stars3.53.00.00.02.40.81.3ANIKAnika Therapeutics4.1078 of 5 stars3.52.00.03.63.21.71.3BNXTFBioNxt SolutionsN/AN/AN/AN/AN/AN/AN/AN/AELDNEledon Pharmaceuticals1.9802 of 5 stars3.52.00.00.02.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$10.00491.72% UpsideANIKAnika Therapeutics 3.00Buy$21.3389.80% UpsideBNXTFBioNxt Solutions 0.00N/AN/AN/AELDNEledon Pharmaceuticals 3.00Buy$12.50309.84% UpsideCurrent Analyst Ratings BreakdownLatest BNXTF, ANIK, ELDN, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ANIKAnika TherapeuticsBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.005/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/17/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/16/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/13/2025ANIKAnika TherapeuticsBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $20.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$28.30M6.00N/AN/A$2.12 per share0.80ANIKAnika Therapeutics$117.05M1.38$3.18 per share3.53$14.50 per share0.78BNXTFBioNxt Solutions$280K157.11N/AN/A($0.04) per share-9.50ELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%8/5/2025 (Estimated)ANIKAnika Therapeutics-$82.67M-$3.88N/AN/AN/A-59.40%-2.22%-1.75%N/ABNXTFBioNxt Solutions-$5.72M-$0.04N/A∞N/A-15,638.71%N/A-683.78%N/AELDNEledon Pharmaceuticals-$116.54M-$2.10N/AN/AN/AN/A-189.99%-28.17%N/ALatest BNXTF, ANIK, ELDN, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A3/12/2025Q4 2024ANIKAnika Therapeutics-$0.01-$0.14-$0.13-$1.50$29.00 million$30.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AANIKAnika TherapeuticsN/AN/AN/AN/AN/ABNXTFBioNxt SolutionsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86ANIKAnika TherapeuticsN/A5.343.78BNXTFBioNxt SolutionsN/A0.040.04ELDNEledon PharmaceuticalsN/A6.536.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%ANIKAnika Therapeutics91.53%BNXTFBioNxt SolutionsN/AELDNEledon Pharmaceuticals56.77%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%ANIKAnika Therapeutics7.86%BNXTFBioNxt SolutionsN/AELDNEledon Pharmaceuticals12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableANIKAnika Therapeutics30014.34 million13.50 millionOptionableBNXTFBioNxt Solutions20115.76 millionN/ANot OptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableBNXTF, ANIK, ELDN, and ACIU HeadlinesRecent News About These CompaniesWhat Makes Eledon Pharmaceuticals (ELDN) a New Buy StockMay 23 at 2:58 PM | zacks.com1,100,473 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by AWM Investment Company Inc.May 23 at 8:09 AM | marketbeat.comEquities Analysts Offer Predictions for ELDN Q2 EarningsMay 23 at 8:06 AM | marketbeat.comFrazier Life Sciences Management L.P. Invests $4.85 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 23 at 7:51 AM | marketbeat.comZimmer Partners LP Has $3.09 Million Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 23 at 6:16 AM | marketbeat.comPoint72 Asset Management L.P. Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 22 at 4:42 AM | marketbeat.comWhat is Noble Financial's Estimate for ELDN Q2 Earnings?May 22 at 1:37 AM | americanbankingnews.comVelan Capital Investment Management LP Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 21 at 8:23 AM | marketbeat.comFY2025 EPS Estimates for ELDN Boosted by Cantor FitzgeraldMay 21 at 2:41 AM | marketbeat.comEquities Analysts Issue Forecasts for ELDN FY2025 EarningsMay 20 at 2:39 AM | americanbankingnews.comQ2 EPS Estimate for Eledon Pharmaceuticals Lifted by AnalystMay 20 at 1:49 AM | marketbeat.comLeerink Partnrs Has Optimistic Outlook of ELDN Q2 EarningsMay 20 at 1:49 AM | americanbankingnews.comSphera Funds Management LTD. Buys 1,254,298 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 18, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stockMay 17, 2025 | uk.investing.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Shares Purchased by Ensign Peak Advisors IncMay 17, 2025 | marketbeat.comEledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial ResultsMay 14, 2025 | globenewswire.comAlyeska Investment Group L.P. Increases Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 8, 2025 | marketbeat.comMarshall Wace LLP Invests $331,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 7, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Increase in Short InterestMay 5, 2025 | marketbeat.comAllostery Investments LP Makes New Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 4, 2025 | marketbeat.com683 Capital Management LLC Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNXTF, ANIK, ELDN, and ACIU Company DescriptionsAC Immune NASDAQ:ACIU$1.69 -0.01 (-0.29%) Closing price 04:00 PM EasternExtended Trading$1.69 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Anika Therapeutics NASDAQ:ANIK$11.24 -0.53 (-4.50%) Closing price 04:00 PM EasternExtended Trading$11.24 -0.01 (-0.04%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.BioNxt Solutions OTCMKTS:BNXTF$0.38 +0.01 (+3.71%) As of 05/22/2025 03:09 PM EasternBioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Eledon Pharmaceuticals NASDAQ:ELDN$3.05 +0.03 (+0.99%) Closing price 04:00 PM EasternExtended Trading$3.05 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
